Navigation Links
Jennerex to Present Final Survival Data From Randomized Phase 2 Clinical Trial of JX-594 in Advanced Liver Cancer at American Association for the Study of Liver Diseases Annual Meeting
Date:11/2/2011

SAN FRANCISCO, Nov. 2, 2011 /PRNewswire/ -- Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic products for cancer, today announced that final data from its Phase 2 randomized clinical trial in advanced liver cancer patients will be presented on Monday, November 7, 2011 at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) taking place November 4-8, 2011 in San Francisco, California.  These data, evaluating multi-dose administration of JX-594 in U.S., Korean and Canadian patients with advanced liver cancer, were selected for an oral presentation in the late-breaking oral session of the conference.

The presentation details are as follows:

Abstract Title: "A Randomized, Controlled Phase 2 Clinical Trial of JX-594, a Targeted Multi-Mechanistic Oncolytic Poxvirus, in Patients with Advanced Hepatocellular Carcinoma: Final Data." (Abstract #LB1)
Presenter: Tony Reid, M.D., Ph.D., professor of medicine, hematology/oncology, director of clinical investigation, and the tumor growth, invasion and metastasis program, Moores UCSD Cancer Center at the University of California, San Diego
Session: Late-Breaking Oral Session, November 7, 2011, 2:45 p.m. PT

JX-594: A Multi-Mechanistic Approach To Targeting Cancer

JX-594 is a proprietary, engineered oncolytic virus that is designed to selectively target and destroy cancer cells. JX-594 is designed to attack cancer through three diverse mechanisms of action: 1) the lysis of cancer cells through viral replication, 2) the shutdown of the blood supply to tumors through vascular targeting and destruction, and 3) the stimulation of the body's immune response against cancer cells, i.e., active immunotherapy. Phase 1 and Phase 2 clinical trials in multiple cancer types to date have shown that JX-594, delivered either directly into
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Jennerex Publishes Clinical Data in Journal, Nature, Demonstrating Intravenous Delivery of Multi-Mechanistic Cancer-Targeted Oncolytic Poxvirus JX-594 to Tumors
2. Jennerex Reports Positive Mechanistic Proof-of-Concept Clinical Trial Results Using JX-594 to Treat Metastatic Melanoma
3. Jennerex and Partners Present Positive JX-594 Randomized Phase 2 Clinical Data Showing Promising Survival Benefit in Patients with Advanced Liver Cancer
4. Jennerex to Present JX-594 Liver Cancer Clinical Data at American Society of Gene and Cell Therapy Meeting
5. Jennerex Appoints James M. Burke, M.D. Vice President, Clinical Research
6. Jennerex and Transgene Enter Into an Exclusive Partnership for the Development and Commercialization of JX-594 for the Treatment of Cancers
7. Jennerex Completes Fully Subscribed Private Placement for Aggregate Gross Proceeds of $8.6 Million
8. Jennerex Reports Positive Phase 1 Results for JX-594 Administered Intravenously
9. Jennerex Adds Industry Veteran Paul Cleveland to Board of Directors
10. Jennerex Completes Over-Subscribed Series C Financing for Aggregate Gross Proceeds of Over $5.5 Million
11. Jennerex Closes $5 Million First Tranche of Series C Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... PA (PRWEB) September 02, 2014 ... a new highly efficient, cost effective approach to ... Patent No. 8,820,265 by the U.S. Patent and ... to Opertech. , “Opertech’s taste evaluation ... the first automated high throughput system for rapid ...
(Date:9/2/2014)... Md. , Sept. 2, 2014  Synthetic ... novel anti-infective biologic and drug candidates targeting specific ... today positive results from its final preclinical toxicology ... Administration (FDA) guidance, this bridging study was required ... candidate designed to prevent the devastating effects of ...
(Date:9/2/2014)... Massachusetts , September 2, 2014 ... to BioData,s research and lab management services  ... management service, is pleased to announce the appointment of ... Culot most recently served as VP Marketing and Business ... life science research and clinical applications. Previously, ...
(Date:9/1/2014)... September 01, 2014 The Collaborative ... Diagnostics report provides comprehensive understanding and unprecedented access ... into by the worlds leading life science companies. ... analysis of how and why companies enter collaborative ... prospective partner’s negotiated deals terms provides critical insight ...
Breaking Biology Technology:Opertech Bio Receives U.S. Patent for High-Throughput Taste Evaluation Technology 2Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 2Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 3Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 4Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 5Louis Culot Appointed as BioData's CEO 2Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report by Researchmoz.us 2Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report by Researchmoz.us 3Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report by Researchmoz.us 4
... Bioengineers in the United States have modified a strain ... The research, published in Biotechnology and Bioengineering, ... for strain improvement, a positive development for the biofuel ... mobilis, a bacterium noted for its bio-ethanol producing potential. ...
... Inc. today announced a collaboration with Syngenta Ventures ... low-cost sugars for a variety of industrial applications. ... to Agrivida access to crop technology and intellectual ... Agrivida will bolster its existing technology portfolio, ...
... 2010) -- Nanotechnologists, marine biologists and signal-processing experts from ... Mass., and other U.S. universities have won a $6 ... unlock the secrets of nature,s best camouflage artists. Ultimately, ... of the elegant skin colors and patterns produced by ...
Cached Biology Technology:Bioengineers develop bacterial strain to increase ethanol biofuel production 2Agrivida Announces Collaboration With Syngenta Ventures to Deliver Low-Cost Sugars for Cellulosic Biofuels and Biochemicals 2Nano squid skin: DOD awards $6M for metamaterials research 2Nano squid skin: DOD awards $6M for metamaterials research 3
(Date:9/2/2014)... Washington D.C., September 2, 2014 A study ... Journal of the American Academy of Child ... adolescents diagnosed with a psychiatric diagnosis had an ... exposed to antipsychotics. , Using data from the ... by Dr. Ren Ernst Nielsen, Psychiatry, Aalborg University ...
(Date:9/2/2014)... DURHAM, N.C. -- When you accidentally touch a hot ... know the basic neural circuits involved in sensing and ... out the molecular players. , Duke researchers have made ... molecule involved in pain in worms, and have built ... Sept. 2 in Nature Communications , may help ...
(Date:9/1/2014)... that corals whose calcium-carbonate skeletons form the ... that rely entirely on ocean currents to deliver ... now scientists at MIT and the Weizmann Institute ... they are far from passive, engineering their environment ... enhance their ability to exchange nutrients and dissolved ...
Breaking Biology News(10 mins):Risk of diabetes in children and adolescents exposed to antipsychotics 2Surprising new role for calcium in sensing pain 2Surprising new role for calcium in sensing pain 3Nature's tiny engineers 2Nature's tiny engineers 3
... been prescribed by traditional healers in Brazil to treat a range ... , Now for the first time, researchers at Newcastle University have ... Hyptis crenata otherwise known as Brazilian mint. , Testing ... researcher Graciela Rocha was able to show that when prepared as ...
... Scientists have crystallised a protein that may help gut bacteria ... probiotic producers to identify strains that are likely to be of ... lining the gut to have a beneficial effect, and if they ... stick around long enough to exert their activity," says Dr Nathalie ...
... American College of Medical Toxicology (ACMT) have signed an agreement ... Medical Toxicology (JMT), the official journal of the ACMT, ... the University of Pennsylvania Press. The Journal ... to advancing the science and practice of medical toxicology. ...
Cached Biology News:Got a pain? -- Have a cup of Brazilian mint 2A sticky solution for identifying effective probiotics 2Springer and the American College of Medical Toxicology to work together 2
... Contents include: Microarray hybridization chamber assembly ... top, clamp, thumbscrew) Microarray chamber user guide ... are intended to be cleaned and reused. ... Agilents Catalog Oligo Microarray kits and all ...
Reported to support murine B lymphocytes, hematopoietic tissue from bone marrow, B cells stimulated with lipopolysaccharide, T lymphocytes, and a variety of hybrid cells....
... PEP-126 is an 18 amino acid synthetic peptide whose sequence ... of this peptide is (amino to carboxy terminus): M(1) - A ... P - A - S - P - R - D ... This peptide may be used for neutralization and control experiments ...
Rabbit polyclonal antibody to Glutathione-S-Transferase (GST)...
Biology Products: